Lista de obras - Andreas Wicki - Dominio Público Uruguay

AKT-ions with a TWIST between EMT and MET

artículo científico publicado en 2016

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling

artículo científico publicado en 2016

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

artículo científico publicado en 2018

Determination of the donor:host blood cell ratio after haematological stem cell transplant by means of semiquantitative detection of short tandem repeat polymorphisms

artículo científico publicado en 2002

Diet and cancer

artículo científico publicado en 2011

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

artículo científico publicado en 2010

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

artículo científico publicado en 2018

Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. ⬇️

artículo científico publicado en 2016

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

artículo científico publicado en 2012

Inflammatory cytokines induce podoplanin expression at the tumor invasive front.

artículo científico publicado en 2018

Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?

artículo científico publicado en 2017

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy

artículo científico

Kras in metastatic colorectal cancer

artículo científico publicado en 2010

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial

artículo científico publicado en 2015

Melanoma- finally good news

artículo científico publicado en 2013

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin

artículo científico publicado en 2008

Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications

artículo científico

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

artículo científico publicado en 2017

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study

artículo científico publicado en 2014

Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms

artículo científico publicado en 2020

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I

scientific article published on 10 October 2016

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

artículo científico publicado en 2015

Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.

artículo científico publicado en 2017

SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics

article

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

artículo científico publicado en 2014

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study

artículo científico publicado en 2016

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth

artículo científico publicado en 2011

The potential role of podoplanin in tumour invasion

artículo científico publicado en 2007

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

artículo científico publicado en 2012

Towards More Structure: Comparing TNM Staging Completeness and Processing Time of Text-Based Reports versus Fully Segmented and Annotated PET/CT Data of Non-Small-Cell Lung Cancer

scientific article published on 01 November 2018

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations

artículo científico publicado en 2016

Vemurafenib-induced radiation recall dermatitis: case report and review of the literature

artículo científico publicado en 2014

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma

artículo científico publicado en 2007

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

artículo científico publicado en 2006

[Stivarga shows effectiveness in practice]

artículo científico publicado en 2014

Lista de obras de Andreas Wicki

AKT-ions with a TWIST between EMT and MET

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

Determination of the donor:host blood cell ratio after haematological stem cell transplant by means of semiquantitative detection of short tandem repeat polymorphisms

Diet and cancer

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. ⬇️

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Inflammatory cytokines induce podoplanin expression at the tumor invasive front.

Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy

Kras in metastatic colorectal cancer

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial

Melanoma- finally good news

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin

Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study

Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase I

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.

SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth

The potential role of podoplanin in tumour invasion

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Towards More Structure: Comparing TNM Staging Completeness and Processing Time of Text-Based Reports versus Fully Segmented and Annotated PET/CT Data of Non-Small-Cell Lung Cancer

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations

Vemurafenib-induced radiation recall dermatitis: case report and review of the literature

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

[Stivarga shows effectiveness in practice]